Masoud Vedadi

Dr. Vedadi’s lab focuses on biophysical and biochemical characterization of drug targets, and the discovery of small molecules that modulate their activities. His research particularly focuses on epigenetic targets and histone posttranslational modifications, modulating the function of drug targets through active site directed inhibitors, and antagonizing protein-protein interactions of key protein complexes.

Dr. Vedadi’s lab has characterized SARS-CoV-2 nsp14 and nsp10-nsp16 complex, the two SARS-CoV-2 RNA methyltransferases (MTs) and SARS-CoV-2 nsp13, an ATPase/Helicase. He has discovered and reported various potent inhibitors of nsp14, nsp10-nsp16, and nsp13 within an extensive network of international collaborations. Currently, in addition to his continued efforts in development of SARS-CoV-2 nsp13, nsp14 and nsp10-nsp16 complex inhibitors, his research focuses on the development of therapeutics to prevent future pandemics as a member of the NIH funded QBI COVID-19 Research Group (QCRG), San Francisco, CA, U.S. His research includes coronaviruses that have infected humans so far (OC43, NL63, 229E, MERS, HKU1), and other potential pandemic causing viruses.